Follow the UNITED THERAPEUTICS CORPORATION share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €21.9bn. The latest transaction was disclosed on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: PAUL MAHON. The full history is free.
10
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate UNITED THERAPEUTICS CORPORATION Buy (bullish), based on 12 analysts. Average price target: US$664.33.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,250 of 29,063 companies
76.1
score / 100
Value
61
Quality
91
FCF yld4.7%
Earn yld6.1%
EV/EBITDA12.2x
ROE19%
Gross mgn88%
Net mgn42%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
8,300 shares@ US$547.06540.019% mcap33.0% of flowCommonSEC144:0001950047-26-005618
10 of 10 declarations
Acerca de UNITED THERAPEUTICS CORPORATION
UNITED THERAPEUTICS CORPORATION es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades raras, en particular la hipertensión arterial pulmonar. Enfatiza la innovación y la mejora de la atención al paciente.